AMPH
Amphastar·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 5
Bearish signal 2
Consensus Rating "Strong Buy"
Ample Liquidity
High Gross Profit Margin
Significant Net Income Decline
High Cash/net Profit Ratio
EPS Beats Expectation
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About AMPH
Amphastar Pharmaceuticals, Inc.
A US-based specialty pharmaceutical company that develops, manufactures, and markets injectable and inhalation products
11570 6th Street, Rancho Cucamonga, CA 91730
--
Amphastar Pharmaceuticals, Inc., a California corporation, was founded on February 29, 1996 and merged with amphastar Pharmaceuticals, a Delaware corporation, in July 2004. The company is a professional pharmaceutical company that mainly develops, produces and sells general-purpose and special-purpose injection and inhalation products on the market, including high market entry barriers for the portfolio, general-purpose and patented products. Most of the company's products are used in clinical settings for inpatient or emergency care and are mainly contracted through group purchasing organizations and pharmaceutical wholesalers. The company's products are mainly distributed in pharmaceutical retail.
Earnings Call
Q1/2025
Estimate EPS0.69
Actual EPS0.74
Estimate Revenue173.06M
Actual Revenue170.50M
Amphastar Pharmaceuticals Q1 2025: Unpacking Key Contradictions in BAQSIMI Sales, FDA Timelines, and Market Dynamics
May 08,2025 07:33
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS0.74
Actual EPS0.85
Estimate Revenue173.24M
Actual Revenue174.40M
Amphastar's Q2 2025: Unpacking Contradictions in BAQSIMI Growth, Manufacturing Capacity, and FDA Approvals
Aug 08,2025 01:46
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
AMPH has released its 2025 Q3 earnings. EPS was reported at 0.93, versus the expected 0.83, beating expectations. The chart below visualizes how AMPH has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
AMPH has released its 2025 Q3 earnings report, with revenue of 191.84M, reflecting a YoY change of 0.33%, and net profit of 17.35M, showing a YoY change of -57.09%. The Sankey diagram below clearly presents AMPH's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
